Secondary Antibodies Global Market Report 2025

The secondary antibodies market size has grown rapidly in recent years. It will grow from $1.81 billion in 2024 to $1.99 billion in 2025 at a compound annual growth rate (CAGR) of 10%. Growth in the historic period can be attributed to the increasing adoption of western blotting for protein analysis, greater use of immunohistochemistry in pathology, rising utilization of enzyme-linked immunosorbent assays in diagnostics and research, expanding use of flow cytometry in immunology studies, and increased government and philanthropic funding for life science research.

The secondary antibodies market size is expected to see rapid growth in the next few years. It will grow to $2.88 billion in 2029 at a compound annual growth rate (CAGR) of 9.6%. Growth in the forecast period can be attributed to expanding biopharmaceutical and biotechnology research pipelines, the rising prevalence of cancer and autoimmune diseases, increasing clinical diagnostic testing volumes, growing government and private research funding, and the expanding number of academic research institutes and laboratories. Major trends expected in the forecast period include advances in recombinant antibody production platforms, innovations in site-specific conjugation chemistries for fluorophores and enzymes, development of highly cross-adsorbed formulations to minimize nonspecific binding, expansion of multiplexed fluorescence imaging and spectral flow cytometry, and greater adoption of near-infrared fluorophores for deep-tissue imaging.

The rising prevalence of chronic diseases is expected to drive the growth of the secondary antibodies market in the coming years. Chronic diseases are long-lasting health conditions that typically develop gradually and require ongoing medical care. The increasing prevalence of these diseases is partly attributed to sedentary lifestyles, where prolonged periods of inactivity and low physical activity contribute to conditions like heart disease and diabetes. Secondary antibodies play a crucial role in managing chronic diseases by enabling the precise detection of biomarkers, making them essential for diagnostic assays and tracking disease progression. These antibodies enhance the sensitivity and specificity of assays, facilitating timely and accurate treatment decisions. For instance, in June 2024, the National Health Service (NHS) reported that 3,615,330 individuals in the UK were diagnosed with non-diabetic hyperglycemia or pre-diabetes in 2023, marking an 18% increase compared to 2022. As a result, the growing prevalence of chronic diseases is fueling the demand for secondary antibodies.

Companies in the secondary antibodies market are focusing on developing innovative products, such as recombinant monoclonal antibodies, to improve experimental reproducibility, enhance specificity, and reduce variability between lots. Recombinant monoclonal antibodies are produced in controlled cell line systems using genetically defined sequences, ensuring high consistency and a continuous supply. For example, in October 2023, Proteintech Group Inc., a US-based manufacturer of high-quality antibodies, proteins, and ELISA kits, launched its Multi-rAb Recombinant Secondary Antibodies. These antibodies offer more consistent and reproducible performance since they are generated using controlled recombinant technology, as opposed to animal-derived antibodies, which can exhibit variability. They provide stronger and cleaner signal detection in immunoassays, allowing researchers to visualize low-abundance targets with greater clarity. This innovation improves the accuracy and reproducibility of experiments, particularly in techniques like immunofluorescence and western blotting, leading to more reliable scientific results.

In September 2024, Leinco Technologies Inc., a US-based biotechnology company, acquired QED Bioscience Inc. for an undisclosed amount. This acquisition allows Leinco Technologies to expand its antibody capabilities and enhance its product portfolio, serving research and diagnostic markets globally. QED Bioscience is a US-based company specializing in the development of secondary antibodies and related immunoassay reagents.

Major companies operating in the secondary antibodies market are Thermo Fisher Scientific Inc., Merck KGaA, Agilent Technologies Inc., Bio-Techne Corporation, Miltenyi Biotec GmbH, GenScript Biotech Corporation, Promega Corporation, Sino Biological Inc., Cell Signaling Technology Inc., Fortis Life Sciences, OriGene Technologies Inc., Becton Dickinson and Company, GeneTex Inc., Proteintech Group Inc., Santa Cruz Biotechnology Inc., Creative Diagnostics Inc., Jackson ImmunoResearch Laboratories Inc., SouthernBiotech LLC, MyBioSource Inc., Biotium Inc.

North America was the largest region in the secondary antibodies market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in secondary antibodies report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the secondary antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The secondary antibodies market research report is one of a series of new reports that provides secondary antibodies market statistics, including secondary antibodies industry global market size, regional shares, competitors with a secondary antibodies market share, detailed secondary antibodies market segments, market trends and opportunities, and any further data you may need to thrive in the secondary antibodies industry. This secondary antibodies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Secondary antibodies are antibodies that specifically bind to the constant regions of primary antibodies in a species- and isotype-specific manner and are often conjugated to reporter molecules for detection. They convert primary antibody binding into a visible, fluorescent, or enzymatic signal, enabling the detection, visualization, or quantification of target antigens.

The primary product types of secondary antibodies include monoclonal, polyclonal, and others. Monoclonal secondary antibodies are produced from a single cloned immune cell and recognize only one specific epitope on an antigen. These antibodies are generated using host species such as goat, rabbit, donkey, mouse, and others, and are available in multiple conjugate formats, including enzyme-conjugated, fluorophore-conjugated, unconjugated, and more. They are used in applications such as western blotting, immunohistochemistry, enzyme-linked immunosorbent assays, flow cytometry, and others. End users include pharmaceutical and biotechnology companies, academic and research institutes, hospitals and diagnostic centers, and contract research organizations (CROs).

The secondary antibodies consists of sales of labeled antibodies, unlabeled antibodies, fragment antibodies, conjugated antibodies, fluorescently-labeled antibodies, and biotinylated antibodies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.